Tamoxifen-loaded novel liposomal formulations: evaluation of anticancer activity on DMBA-TPA induced mouse skin carcinogenesis.
OBJECTIVE
Tamoxifen (TAM) is a non-steroidal estrogen receptor modulator known for its anticancer activity. Apart from marked breast cancer activity, this drug has also shown potential in treating other types of cancers including skin cancers. TAM is reported to be associated with serious side effects primarily due to its systemic distribution. The localized delivery of this drug in this regard would be highly beneficial with respect to safety as well as efficacy.


METHODS
In the current studies, an endeavor has been made to investigate the efficacy of topically applied liposome-encapsulated TAM on skin cancer model. The drug was encapsulated in phospholipid-based vesicular systems viz. conventional liposomes and elastic liposomes. Incidence of papillomas and histopathological examination were employed to determine the efficacy of the tested formulations.


RESULTS
The results demonstrated carrier-dependent strong inhibition of skin carcinogenesis with encapsulated drug vis-à-vis drug in the solution form. The encouraging findings from the current work construe immense potential of the TAM-loaded liposomal systems in the management of skin cancer.
Department of Pharmaceutics, School of Pharmaceutical Sciences, Lovely Faculty of Applied Medical Sciences, Lovely Professional University, Jalandhar, Punjab, India.
Amit
A
Bhatia
Bhupinder
B
Singh
Kaisar
K
Raza
Anshuman
A
Shukla
Basant
B
Amarji
Om Prakash
OP
Katare
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000633:toxicity*; D000279:Administration, Cutaneous; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D003043:Cocarcinogenesis; D004339:Drug Compounding; D016503:Drug Delivery Systems; D005260:Female; D008081:Liposomes; D051379:Mice; D012878:Skin Neoplasms / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D013629:Tamoxifen / Q000008:administration & dosage / Q000627:therapeutic use*; D013755:Tetradecanoylphorbol Acetate / Q000633:toxicity*; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D008081:Liposomes; D013629:Tamoxifen; D015127:9,10-Dimethyl-1,2-benzanthracene; D013755:Tetradecanoylphorbol Acetate